Immunotherapeutic Potential of TGF- β Inhibition and Oncolytic Viruses.

Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses. Trends Immunol. 2020 Mar 26;: Authors: Groeneveldt C, van Hall T, van der Burg SH, Ten Dijke P, van Montfoort N Abstract In cancer immunotherapy, a patient's own immune system is harnessed against cancer. Immune checkpoint inhibitors release the brakes on tumor-reactive T cells and, therefore, are particularly effective in treating certain immune-infiltrated solid tumors. By contrast, solid tumors with immune-silent profiles show limited efficacy of checkpoint blockers due to several barriers. Recent discoveries highlight transforming growth factor-β (TGF-β)-induced immune exclusion and a lack of immunogenicity as examples of these barriers. In this review, we summarize preclinical and clinical evidence that illustrates how the inhibition of TGF-β signaling and the use of oncolytic viruses (OVs) can increase the efficacy of immunotherapy, and discuss the promise and challenges of combining these approaches with immune checkpoint blockade. PMID: 32223932 [PubMed - as supplied by publisher]
Source: Trends in Immunology - Category: Allergy & Immunology Authors: Tags: Trends Immunol Source Type: research